U.S. health regulator extends review of Biogen’s ALS drug – Reuters
Oct 17 (Reuters) – The U.S. Food and Drug Administration has extended the review of Biogen Inc’s (BIIB.O) experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three … [read more]